MedTrace Logo

The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

NCT04885582 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-05-13

No results posted yet for this study

Summary

Liver transplantation has become the accepted treatment option for advanced liver failure in recent years. In addition to the increase in the number of centers performing transplant and the decrease in complication rates depending on the experience gained, the most common biliary complications did not improve at the desired level. For this reason, studies in this field are frequent today.

The structural complexities of HLA antigens have been the subject of investigation in recent years. With the development of DNA and RNA amplification methods; It is increasingly difficult for physicians to keep up with the increasing burden of knowledge regarding the genetic aspects of these antigens. Concrete benefits of this gene complex, which has been investigated in various fields and preserves its mystery, have not been determined in liver transplant patients. However, there are publications showing its connection with the bile epithelium in liver transplantation and its relationship with the disappearing bile duct syndrome. In this study, our aim is to explain whether the bile duct complications, which appear like a continuous wall and can lead to frightening pictures, are related to HLA tissue compatibility.

Conditions

  • Liver Transplant; Complications
  • HLA Antigens

Interventions

OTHER

HLA antigen results

HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.

Sponsors & Collaborators

  • Inonu University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-10
Primary Completion
2019-05-10
Completion
2020-05-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885582 on ClinicalTrials.gov